Disease duration of 9.5 years on average in the mutation carrier group was longer than the PD group in the JH‐PDBP cohort at baseline (6.9 years), with a corresponding worse MoCA score distribution in the LRRK2 mutation group than the JH‐PDBP group (Supplementary Table S2). Here, LRRK2 is linked to Parkinson disease.